Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
← catalyst calendarSponsored by ArriVent BioPharma, Inc. (industry) · AVBP — their whole pipeline →. With Allist Pharmaceuticals, Inc..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
398actual
Sites
208
Countries
Australia, Brazil, Canada +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-01 | actual | When the study began enrolling |
| Primary completion | 2025-08-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-15 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Lung Cancer
- EGFR Exon 20 Mutations
Interventions
- Drug: furmonertinib 240 mg oral, daily — also filed as AST2818
- Drug: furmonertinib 160 mg oral, daily — also filed as AST2818
- Drug: platinum-based chemotherapy
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS) determined by blinded independent central review (BICR)
measured Up to 32 months after first dose
Permalink · AVBP's whole pipeline · Catalyst calendar · Every registered study · What changed